BSD Medical Ships BSD-2000 Hyperthermia System to University of California San Francisco Medical Center

  BSD Medical Ships BSD-2000 Hyperthermia System to University of California   San Francisco Medical Center  Business Wire  SALT LAKE CITY -- July 31, 2014  BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Company has shipped a BSD-2000 Hyperthermia System (BSD-2000) to the prestigious University of California San Francisco Medical Center (UCSF Medical Center). UCSF Medical Center is one of the nation's top 10 hospitals and is recognized throughout the world for innovative patient care and advanced technology (http://www.ucsfhealth.org/about/). UCSF Medical Center is one of the premier providers of cancer care in the world. The UCSF Medical Center Comprehensive Cancer Center received the prestigious designation of "comprehensive" from the National Cancer Institute and ranks sixth nationwide in National Cancer Institute research grants. UCSF Medical Center has 7,000 employees and numerous locations.  “We are excited to have the BSD-2000 placed in this prestigious cancer care facility," stated Brian Ferrand, BSD's Vice President of Domestic Sales. UCSF is one of the world's leading medical centers and has a long history of providing innovative therapies, including hyperthermia. UCSF has previously purchased a BSD-500 Hyperthermia System from BSD. We are pleased they have decided to also offer the innovative capabilities of the BSD-2000 to their patients."  About the BSD-2000 Hyperthermia System  The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE marking approval is also recognized in many countries outside of the EU.  About BSD Medical Corporation  BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.  This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.  Contact:  BSD Medical Corporation Tricia Ross, (310) 622-8226 tross@finprofiles.com  
Press spacebar to pause and continue. Press esc to stop.